A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
 


Dr. JudesPoirier, PhD
Full Professor


Alzheimer’s/neurodegenerative diseases
Genetics
Pharmacogenomics


Douglas Mental Health University Institute
6825 LaSalle Blvd
Montreal
Quebec
H4H 1R3
514-761-6131 ext. 6153
514-888-4094

judes.poirier@mcgill.ca


Centre for Studies in Aging
6875 LaSalle Blvd
Montreal
Quebec
H4H 1R3
514-761-6131 ext. 6153
514-888-4094



Born in Montreal, Dr. Poirier is a full professor of medicine and psychiatry at McGill University, Director of the Molecular Neurobiology Unit at the Douglas University Mental Health Institute, and a senior scientist of the Canadian Institute for Aging Research. Dr. Poirier has made key contributions to the advancement of scientific research on Alzheimer's and Parkinson's disease. He is internationally renowned for his works on the role of apolipoprotein E in the normal and injured brain and in the genetics of Alzheimer's disease. Besides his seminal contribution in the field of the neurobiology of apolipoprotein E, he has been a pioneer in the establishment of the pharmacogenomic bases of brain disease treatments.


Undergraduate: BSc Biochemistry, Université de Montreal
Graduate: PhD Neurochemistry, Clinical Research Institute of Montreal

Research Associate: Neurobiology, University of Southern California


Knight, Order of Quebec, Canada
Honoris Causa, University of Monpellier, France

Society for Neuroscience, International Society for Neurochemistry



Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E phenotype and Alzheimer's disease. Lancet. 1993;342:697-699.

Poirier J, Aubert I, Quirion R, Farlow M, Nalbantoglu J, Gilfix BG, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. 1995;92:12260-12264.

Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Massicotte G, Julien JP, Shapiro ML. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997 May 29;387(6632):500-555.

Farlow M, Lahiri DK, Poirier J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Azlheimer's disease. Neurology. 1998;50:669-677.

Valastro B, Ghribi O, Poirier J, Krzywkowski P, Masicotte G. AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. Neurobiol. 2001;Aging22(1):9-15.

De Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J. Prediction of cognitive decline in normal elderly subjects with FDG-PET. Proc. Natl. Acad. Sci. 2001;98:10966-10871.

Champagne D, Pearson D, Dea D., Rochford J and Poirier J. Cholesterol lowering drug Probucol increases apolipoprotein E production in the hippocampus of aged rats: implication for Alzheimer’s disease. Neuroscience. 2003;121:99-110.

Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Medicine. 2003;9:94-101.

Blain JF, Aumont N,Théroux L, Dea D, Poirier J. Intronic polymorphisms of the lipoprotein lipase are associated with the risk and pathology of common Alzheimer’s disease. Eur. J. Neurosci. 2006;24(5):1-5.

Leduc V, Dea D , Robitaille Y, Poirier J. Involvement of Paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 2009;30:1823-1830.